Cryoport, Inc.
NASDAQ•CYRX
CEO: Mr. Jerrell W. Shelton
セクター: Industrials
業種: Integrated Freight & Logistics
上場日: 2005-08-22
Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.
連絡先情報
時価総額
$498.19M
PER (TTM)
6.2
35.7
配当利回り
--
52週高値
$11.45
52週安値
$5.21
52週レンジ
順位63Top 94.0%
1.8
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
弱い • 1.8 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025
財務ダッシュボード
Q4 2025 データ
売上高
$45.45M+0.00%
直近4四半期の推移
EPS
-$0.21+0.00%
直近4四半期の推移
フリーCF
-$4.55M+0.00%
直近4四半期の推移
2025 Annual 決算ハイライト
主なハイライト
Total Revenue Growth Total revenue reached $176.2M, marking a 12.4% increase. Life Sciences Services revenue grew 17.6% to $96.5M.
Profitability Reversal Achieved Net Income of $78.3M in 2025, a significant shift from Net Loss of ($114.8M) reported in 2024.
Strategic Divestiture Gain Completed CRYOPDP divestiture for $133.0M in Q2 2025, resulting in a $117.0M gain recognized in operations.
CGT Market Support Supported 760 clinical trials globally; 20 commercial therapies generated $33.4M revenue, increasing 28.6%.
リスク要因
Component Supply Dependency Dependence on third-party component availability; delays or increased procurement costs could adversely affect financial performance.
Global Regulatory Exposure Operations face risks from changing international trade policies, currency fluctuations, and complex governmental regulations.
Product Liability Exposure Risk of liability claims exceeding insurance coverage, particularly concerning products used in human reproductive medicine.
Cybersecurity System Failure Critical information systems face constant cyberattacks; system compromise could materially harm operations and reputation.
見通し
Digital Strategy Enhancement Established Enterprise Technology Group (ETG) to drive digital initiatives, integrating AI and advanced analytics across platforms.
Infrastructure Expansion Plans Opened Paris Global Supply Chain Center in 2025; planning another center in Santa Ana, California, late 2026.
MVE System Connectivity Plans to introduce MVE CryoVerse Ecosystem in 2026 for real-time monitoring and enhanced compliance visibility.
Future Capital Requirements Management recognizes potential need for additional equity or debt capital until sustained profitability is achieved.
同業比較
売上高 (TTM)
$2.50B
$1.87B
$1.83B
粗利益率 (最新四半期)
89.1%
59.9%
48.4%
主要指標
銘柄コード | 時価総額 | PER (TTM) | ROE (TTM) | 負債比率 |
|---|---|---|---|---|
| CODI | $783.96M | -3.4 | -40.4% | 61.8% |
| SWBI | $660.73M | 54.2 | 3.3% | 20.2% |
| FWRD | $600.79M | -5.5 | -77.1% | 78.7% |
長期トレンド
直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
3.5%
緩やかな成長
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
50%
キャッシュフローに注意が必要
深度リサーチ
次回決算:2026年4月30日
EPS:-$0.22
|売上高:$44.87M
財務データ
決算説明会
財務レポート
ニュース
損益計算書
バランスシート
キャッシュフロー計算書
財務比率
変化率
損益計算書 | 直近12ヶ月 |
|---|
データなし